Cargando cotizaciones...
Previsión
No hay datos de analistas disponibles para esta empresa.
Noticias Ir al feed de noticias
Psyence BioMed to advance development of ibogaine after Trump announcement
Psyence BioMed said it intends to support development of ibogaine after President Trump signaled progress on regulatory steps and research funding. CEO Jody Aufrichtig and CFO Warwick Corden‑Lloyd are meeting with stakeholders in Texas to discuss clinical, regulatory and policy opportunities. The company, via PsyLabs, has access to GMP‑compliant manufacturing and stocks of ibogaine hydrochloride, but stressed that ibogaine remains controlled in the US and no clinical trials for the planned products have yet been conducted. » Más en de.investing.com
Psyence Biomedical reports quarterly loss of $0.51 per share
Psyence Biomedical released the numbers for the quarter ended 30 September 2025 at the investor conference on 20 November 2025 and reported an EPS of -$0.51. By comparison, the company had earned $4.14 per share in the same period a year earlier. » Más en finanzen.net
Datos financieros de la empresa
| (EUR) | sep 2025 | |
|---|---|---|
| Ingresos | 0,00 | - |
| Beneficio bruto | −1,13k | - |
| Beneficio neto | −641,87k | - |
| EBITDA | −638,39k | - |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 70,99k€ |
Número de acciones | 19,02k |
Máximo/mínimo de 52 semanas | 185,70€ - 1,65€ |
| Dividendos | No |
Beta | 1,67 |
Ratio P/E | 0,00 |
Ratio PEG | 0,00 |
Ratio P/B | 0,00 |
Ratio P/S | 0,00 |
Perfil de la empresa
| Nombre | PSYENCE BIOMEDICAL LTD. |
| CEO | Jody Aufrichtig |
| Empleados | 12 |
Descubrir activos
Los accionistas de PSYENCE BIOMEDICAL LTD. también invierten en los siguientes activos
